#United States #Berwyn #Nordic Pharma #LACRIFILL #Dry Eye Gel

Significant Milestone for Nordic Pharma, Inc.

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has recently marked a major milestone by successfully treating over 100,000 patients with its innovative LACRIFILL® Canalicular Gel designed for dry eye symptom management. This achievement highlights the accelerated acceptance and effectiveness of the treatment within the eye care community.

In response to physician feedback, Nordic Pharma has announced that they will now include cannulas with their syringe shipments of LACRIFILL. This addition is aimed at increasing convenience for healthcare providers and ensuring an efficient application process. The decision reflects the company's commitment to incorporating medical professionals’ insights into their service improvement strategies.

Eric Donnenfeld, MD, Board Chair of OCLI Vision and NYU Langone Health, emphasized the necessity of controlling ocular surface health, particularly around eye surgeries. He stated, "LACRIFILL® Canalicular Gel has consistently delivered on its purpose, providing meaningful ocular surface control." Dr. Donnenfeld further underscored its unique approach, differentiating it from traditional punctal plugs.

Mile Brujic, OD, FAAO, from Premier Vision Group, shared his transformative experience with the gel in his practice, stating, "Using LACRIFILL as a tool to improve dry eye disease has been a true game-changer. Not only does it support strong visual outcomes, but it also significantly improves patient comfort. The clinical data supporting its use is compelling and confirms the benefits we observe in our patients."

The LACRIFILL gel is packaged in pre-filled syringes, sufficient for treating both upper and lower canaliculi in both eyes. The gel can be easily inserted using a cannula tip placed in the punctum, effectively flowing into the lacrimal sac to temporarily block tear drainage. The product is conveniently packaged in sets of ten syringes, each now accompanied by ten cannulas.

Launched in the United States in May 2024 after FDA clearance, LACRIFILL was created with the goal of addressing the needs of a substantial portion of the population experiencing dry eye conditions, which affects approximately 6.8 percent of adults in the US. Jai Parekh, MD, MBA, Chief Commercial Officer of Eye Care US, expressed gratitude for the fast acceptance rate among optometrists and ophthalmologists, illustrating Nordic Pharma's mission to innovate dry eye disease management.

To further showcase their product, Nordic Pharma, Inc. will hold live demonstrations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting scheduled for April 10-13 in Washington, DC. Esteemed professionals will conduct demonstrations at their booth, allowing attendees to witness the preparation of the ocular surface with the LACRIFILL Canalicular Gel firsthand.

This remarkable achievement signifies a positive trend towards proactive management of dry eye disease, promoting better patient outcomes across the board. For those interested in learning more about LACRIFILL Canalicular Gel, additional details are available on their website at lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is a privately owned, mid-sized international pharmaceutical company focused on the development and commercialization of specialized products. Their strategic growth has been achieved through targeted developments and acquisitions, particularly in areas related to Eye Care, Rheumatology, and Women’s Health. The group has established a significant presence across Europe and is continuing to expand its reach globally.

Nordic Pharma, Inc. represents a commitment to innovation, collaboration with established global biopharmaceutical companies, and the introduction of high-quality biotech-derived medicines to the health market. As the landscape of eye care continues to evolve, Nordic Pharma remains dedicated to enhancing patient care through their advanced treatment options.